Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in oncology. Utilizing its proprietary drug discovery platform that merges advanced genomics with precision medicine, the company is committed to creating treatments that directly target the mutations responsible for cancer progression. Erasca boasts a strong pipeline of clinical-stage candidates designed to inhibit crucial tumor growth pathways, reinforcing its position as a leader in improving therapeutic standards and patient outcomes in cancer care. Strategic partnerships within the oncology research community bolster Erasca's reputation as a vital innovator in the biopharmaceutical landscape.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$16.28
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 11, 2026 | $-0.12 | $-0.14 | Miss -16.7% | $-0.14 | $0 | $0 | — | 1D Pre-1.6% | On-Day+1.0% | 1D Post+1.5% |
Q ended Mar 31, 2026 Reported May 11, 2026 | $-0.23 | $-0.60 | Miss -160.9% | $-0.60 | $0 | $0 | — | 1D Pre-2.7% | On-Day+3.2% | 1D Post-0.6% |
Q ended Dec 31, 2025 Reported Mar 12, 2026 | $-0.10 | $-0.10 | Met 0.0% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-0.5% |
| On-Day-5.5% |
| 1D Post-7.0% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.10 | $-0.11 | Miss -10.0% | — | $0 | $0 | — | 1D Pre+3.1% | On-Day+12.3% | 1D Post-4.2% |